20776-55-0

Basic information

• Product Name: 2-amino-3-iodo-benzoic acid
• Synonyms: 2-amino-3-iodo-benzoic acid;Anthranilic acid, 3-iodo-
• CAS NO: 20776-55-0
• Molecular Formula: C₇H₆INO₂
• Molecular Weight: 263.03
• Mol File: 20776-55-0.mol

Chemical Properties

• Melting Point: 137 °C
• Boiling Point: 366.5 °C at 760 mmHg
• Flash Point: 175.5 °C
• Appearance: /
• Density: 2.082g/cm³
• Vapor Pressure: 5.13E-06mmHg at 25°C
• Refractive Index: 1.728
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.59±0.10(Predicted)
• CAS DataBase Reference: 2-amino-3-iodo-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-3-iodo-benzoic acid(20776-55-0)
• EPA Substance Registry System: 2-amino-3-iodo-benzoic acid(20776-55-0)

Safety Data

• Hazardous Substances Data: 20776-55-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-amino-3-iodo-benzoic acid is used as a building block in organic synthesis for the creation of various chemical compounds. Its unique structure allows for the formation of new molecules with potential applications in different fields.
Used in Pharmaceutical Industry:
2-amino-3-iodo-benzoic acid is used as a key component in the development of new drugs and pharmaceutical formulations. Its presence in the molecular structure can contribute to the therapeutic properties of the final product.
Used in Medicinal Chemistry:
2-amino-3-iodo-benzoic acid is utilized in medicinal chemistry for the exploration of its potential biological activity. Studies are conducted to understand its therapeutic properties and how it can be incorporated into effective treatments.
Used in Drug Development:
2-amino-3-iodo-benzoic acid is employed in drug development as a promising candidate for the creation of novel therapeutic agents. Its unique structure and potential biological activity make it an important component in the advancement of pharmaceutical research.

InChI:InChI=1/C7H6INO2/c8-5-3-1-2-4(6(5)9)7(10)11/h1-3H,9H2,(H,10,11)

Upstream product

• 20780-78-3 7-iodoisatin 
• 99-05-8 meta-aminobenzoic acid 
• 618-51-9 3-Iodobenzoic acid 
• 117500-16-0 2'-hydroxyimino-2-iodoacetanilide 
• 118-92-3 anthranilic acid 

Downstream Products

• 85063-06-5 2-(o-methyl phenoxymethyl)-8-iodo anthranil 
• 83793-87-7 2-(3,5-Dimethylphenoxymethyl)-8-iodoanthranil 
• 118-92-3 anthranilic acid 
• 679426-09-6 3-iodo-2-(pyrrol-1-yl)benzoic acid 
• 913286-73-4 benzyl 2-amino-3-iodobenzoate 
• 77150-36-8 8-iodoquinazolin-4(1H)-one 
• 437998-32-8 2-amino-3-iodobenzamide 
• 1615254-73-3 (S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-8-iodoquinazolin-4(3H)-one 
• 1615252-74-8 (S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile 
• 1615254-38-0 (S)-tert-butyl (1-(3-(3,5-difluorophenyl)-8-iodo-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)carbamate 
• 85063-05-4 8-Iodo-2-phenoxymethyl-benzo[d][1,3]oxazin-4-one 
• 68501-67-7 8-Iodo-2-phenyl-benzo[d][1,3]oxazin-4-one 

Relevant articles and documents

A High-Throughput Assay for Arylamine Halogenation Based on a Peroxidase-Mediated Quinone-Amine Coupling with Applications in the Screening of Enzymatic Halogenations

Arylhalides are important building blocks in many fine chemicals, pharmaceuticals and agrochemicals, and there has been increasing interest in the development of more "green" halogenation methods based on enzyme catalysis. However, the screening and development of new enzymes for biohalogenation has been hampered by a lack of high-throughput screening methods. Described herein is the development of a colorimetric assay for detecting both chemical and enzymatic arylamine halogenation reactions in an aqueous environment. The assay is based on the unique UV/Vis spectrum created by the formation of an ortho-benzoquinone-amine adduct, which is produced by the peroxidase-catalysed benzoquinone generation, followed by Michael addition of either a halogenated or non-halogenated arylamine. This assay is sensitive, rapid and amenable to high-throughput screening platforms. We have also shown this assay to be easily coupled to a flavin-dependent halogenase, which currently lacks any convenient colorimetric assay, in a "one-pot" workflow.

DIHYDROOROTATE DEHYDROGENASE INHIBITORS

The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.

METHOD FOR PRODUCING 2-AMINO-5-IODOBENZOIC ACID

A method for producing 2-amino-5-iodobenzoic acid which comprises bringing 2-aminobenzoic acid (A) and molecular iodine (B) into reaction with each other in the liquid phase in the presence of an oxidizing agent. Hydrogen peroxide is preferable as the oxidizing agent. This method does not require a step for purifying 2-amino-5-iodobenzoic acid or a step for recovering iodine, and 2-amino-5-iodobenzoic acid having excellent quality can be produced economically advantageously with a great yield. The product can be advantageously used as an intermediate for drugs, an agricultural chemical and a raw material for functional chemicals.

Design, Synthesis, and Evaluation of Novel Thienopyrrolizinones as Antitubulin Agents

Herein, we describe the structure-activity relationship study of a new 3-aryl-8H-thieno[2,3-b]pyrrolizin-8-one series of antitubulin agents. The pharmacological results from the National Cancer Institute in vitro human disease oriented tumor cell line screening allowed us to identify compound 1d (NSC 676693) as a very efficient antitumoral drug in all cancer cell lines tested. This prompted us to define the structural requirements essential for this antiproliferative activity. Among all analogues synthesized in this study, compound lo was the most promising, being 10-fold more potent than compound Id. Its activity over a panel of nine tumoral cell lines was in the nanomolar range for all of the histological types tested, and surprisingly, the resistant KB-A1 cell line was also sensitive to this compound. Moreover, a flow cytometric study showed that L1210 cells treated by the most potent compounds were arrested in the G2/M phases of the cell cycle with a significant percentage of cells having reinitiated a cycle of DNA synthesis without cell division. This interesting pharmacological profile, resulting from inhibition of tubulin polymerization, encouraged us to perform preliminary in vivo studies that led to a new prodrug chemical approach.